Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale ... In September 2024, the FDA approved Cobenfy, ...

Schizophrenia drug Cobenfy, ... Approved by the FDA to treat schizophrenia in September 2024, Cobenfy boasts a novel mechanism, targeting cholinergic receptors rather than dopamine receptors.